About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
REHOVOT, ISRAEL—July 16, 2020—Choosing the right drug for each cancer patient is key to successful treatment, but physicians currently have few reliable pointers to guide them in designing treatment protocols. Researchers at the Weizmann Institute of Science and the Broad Institute of MIT and Harvard have now developed a new method...
July 16, 2020
REHOVOT, ISRAEL—June 2, 2020—Cancer cells are comfy havens for bacteria. That conclusion arises from a rigorous study of over 1,000 tumor samples of different human cancers.
June 02, 2020
REHOVOT, ISRAEL—February 18, 2020—One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.
February 18, 2020
Ewing sarcoma is a bone cancer that appears mainly in teenagers. Caused by a single defective gene, once it spreads to distant organs it is hard to treat. Researchers at the Weizmann Institute of Science have now discovered molecular interactions underlying Ewing sarcomas and proposed a potential treatment that has shown promise in a study in mice. These findings were published in Cell Reports.
October 02, 2019
Diversity – at least among cancer cells – is not a good thing. Now, research from the Weizmann Institute of Science shows that in melanoma, tumors with cells that have differentiated into more diverse subtypes are less likely to be affected by the immune system, thus reducing the chance that immunotherapy will be effective. The findings of this research, which were published in Cell, may provide better tools for designing personalized protocols for cancer patients, as well as pointing toward new avenues of research into anti-cancer vaccines.
September 12, 2019
Steba Biotech, a privately owned company, has, in collaboration with scientists at the Weizmann Institute of Science, conducted extensive research and development on the prostate cancer treatment TOOKAD® – and now has received marketing authorization to make it available in 31 European countries. Following this regulatory approval, the first patients are currently being treated in top Israeli, German, English, and Italian medical centers.
April 29, 2019
Cancer arises when cells lose control. Deciphering the “blueprint” of cancer cells – outlining how cancer cells hijack specific pathways for uncontrolled proliferation – will lead to more efficient ways to fight it. Now, in a joint effort, scientists from the Weizmann Institute of Science and clinicians from major hemato-oncology departments in Israel have successfully created detailed profiles of myeloma cancer in both pre-cancer stages, in newly diagnosed multiple myeloma patients, as well as post-treatment and relapse. These detailed blueprints will help in future precision diagnosis and treatment of this disease.
December 06, 2018
With new immunotherapy treatments for melanoma, recovery rates have risen dramatically – in some cases to around 50%. But they could be much higher. A new study led by researchers at the Weizmann Institute of Science showed, in lab dishes and animal studies, that a highly personalized approach could help the immune cells improve their ability to recognize the cancer and kill it. The results of this study were published in Cancer Discovery.
September 12, 2018
When the body makes use of nitrogen, it generates from the leftovers a nitrogenous waste substance called urea in a chain of biochemical reactions that take place in the liver, which are known as the urea cycle. As a result of this cycle, urea is expelled into the bloodstream, and is later excreted from the body in the urine. In previous research, Dr. Ayelet Erez of Weizmann’s Department of Biological Regulation showed that one of the enzymes in the urea cycle has been inactivated within many cancerous tumors, thus increasing the availability of nitrogen for the synthesis of an organic substance called pyrimidine which, in turn, supports RNA and DNA synthesis and cancerous growth.
August 2018
©2020 American Committee for the Weizmann Institute of Science